These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15877721)

  • 21. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
    Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
    Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
    Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
    Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacotherapy in schizophrenia--comparison of second generation antipsychotic agents].
    Melamed Y; Finkel B; Barak Y; Zipris P; Oyffe I; Weizman A; Bleich A
    Harefuah; 2005 Apr; 144(4):285-90, 301. PubMed ID: 15889614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual dysfunction in schizophrenia: focus on recent evidence.
    Baggaley M
    Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.
    Novick D; Bousono M; Suarez D; Olivares JM; Montejo AL; Haro JM; Edgell ET; Ratcliffe M;
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):972-82. PubMed ID: 16023776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
    Awad AG
    CNS Drugs; 2019 Jan; 33(1):1-8. PubMed ID: 30511350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How antipsychotics work: the patients' perspective.
    Mizrahi R; Bagby RM; Zipursky RB; Kapur S
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):859-64. PubMed ID: 15908094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Subjective aspects of pharmacotherapy in schizophrenia during implementation of chlorpromazine in Poland--a review].
    Murawiec S
    Psychiatr Pol; 2003; 37(4):657-67. PubMed ID: 14560494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Subjective aspects of psychopharmacology in schizophrenia].
    Murawiec S
    Psychiatr Pol; 1999; 33(1):25-35. PubMed ID: 10786213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic dysphoria: towards a new synthesis.
    Voruganti L; Awad AG
    Psychopharmacology (Berl); 2004 Jan; 171(2):121-32. PubMed ID: 14647964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    Awad AG; Voruganti LN
    Can J Psychiatry; 2004 May; 49(5):297-302. PubMed ID: 15198465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):1-4. PubMed ID: 20121558
    [No Abstract]   [Full Text] [Related]  

  • 40. Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.
    Wu HE; Okusaga OO
    Psychiatr Q; 2015 Jun; 86(2):199-205. PubMed ID: 25164199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.